Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Brii Bio In-licenses China Rights to Second HBV mAb from Vir

publication date: Jul 5, 2022

Beijing’s Brii Biosciences exercised an option to acquire China rights to a neutralizing monoclonal antibody for HBV from Vir Biotechnology. Brii is currently testing a combination of two Vir assets with the goal of offering a functional cure for HBV. It now owns China rights to both candidates. In a US Phase II trial, Vir showed that the combination of the two molecules offers a better response than either one alone. In 2018, Brii was formed with $260 million in initial capital and options on four Vir infectious disease therapies. More details...

Stock Symbol: (HK: 2137)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital